Monopar Therapeutics (MNPR): Shareholders' Equity
$137.83M
As of 2025-12-31
$130.85M
As of 2026-06-30
+139.0%
3-year compound annual growth
+54.4%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $137.83M | +150.4% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $55.04M | +885.0% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $5.59M | -44.6% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $10.09M | -46.7% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $18.94M | +20.7% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $15.69M | +24.3% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $12.63M | +82.5% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $6.92M | -28.1% | 2020-03-27, Balance as of period end |
| 2017-12-31 | $9.62M | +239.8% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $2.83M | n/a | 2018-03-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | 2025-12-31 | $137.83M | +150.4% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare MNPR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗